Campbell, P. B.Tolson, T. A.Yoder, L.Loesch, JulieKrahenbuhl, J. L.2011-04-292011-05-172011-04-292011-05-171987-11Clinical and Experimental Immunology; 70:2 p. 289-297http://hdl.handle.net/10342/3460Because the accumulation and activation of mononuclear phagocytes are critical to the host response to intracellular microbial pathogens, we evaluated mechanisms of peripheral monocyte leucotactic regulation in leprosy. Plasma from 53 of 67 patients was found to inhibit the locomotion of normal human monocytes. Neither the prevalence nor the magnitude of plasma leucotactic inhibitory activity correlated with disease histology or duration, type or duration of chemotherapy, or history of erythema nodosum leprosum. Plasma leucotactic inhibitory activity resided principally in a non-immunoglobulin, cell-directed inhibitor of 230,000 daltons molecular weight. Fractionation of plasma from patients with lepromatous leprosy revealed an additional, immunoglobulincontaining inhibitor of approximately 400,000 daltons weight, possibly an IgG-IgA immune complex. Production of leucotactic inhibitors by unstimulated and concanavalin A-stimulated peripheral mononuclear cells was normal; however, cutaneous explants from these patients spontaneously produced the 230,000 dalton leucotactic inhibitor in vitro. The ability of the lesions of leprosy to impede monocyte traffic may be an important pathogenetic mechanism. Originally published Clinical and Experimental Immunology, Vol. 70, No. 2, Nov 1987en-USAuthor notified of opt-out rights by Cammie Jennings prior to upload of this article.LeprosyMonocytesLeucotaxisInhibitorArticlePMC1542101